![blood magic maps blood magic maps](https://static-cdn.jtvnw.net/ttv-boxart/Minecraft-285x380.jpg)
To validate the MAP’s role as a response biomarker, researchers computed MAPs for 615 patients who underwent hematopoietic cell transplantation at 20 MAGIC centers across the globe. “These two biomarkers in the equation act as a ‘liquid biopsy’ that tells you about the extent of damage to the crypts, and it’s the crypt damage that really determines whether the gastrointestinal tract can heal.†Ferrara, MD, DSc, Professor and Director of the Hematologic Malignancies Translational Research Center at the Icahn School of Medicine at Mount Sinai.
![blood magic maps blood magic maps](https://cdn.shopify.com/s/files/1/0556/6962/0933/products/https___trade.games-workshop.com_assets_2022_06_Soulblight_Grey_18ml_2022_New_1024x1024.png)
![blood magic maps blood magic maps](https://www.gry-online.pl/galeria/html/poradniki/20/m5_avle.jpg)
€œThe exciting thing about the MAP is that it acts as a combination of two biomarkers that are put together into an equation,†explained corresponding author James L. Srinagesh, from the Icahn School of Medicine at Mount Sinai, received the Outstanding Abstract Achievement Award for a medical student at the meeting. The study’s first author, Hrishikesh K. These findings were published in Blood Advances and presented at the 2019 American Society of Hematology Annual Meeting. MAP, which is computed from levels of two serum biomarkers, also more accurately predicted durability of response to anti-GVHD therapy compared with changes in clinical symptoms. Measuring damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD) via the Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP) tool successfully predicted patients’ long-term outcomes, including 6-month non-relapse mortality (NRM).